VIRUSBANK PLATFORM INFRASTRUCTURE
Infrastructure
The VirusBank Platform comprises unique, state-of-the-art research facilities at the Arenberg Accelerator and the Rega Institute in Leuven, capable of supporting all in vitro and in vivo research with highly pathogenic viruses and drug discovery of anti-infective modalities.
Our research is performed in:
- A fully equipped 600 m² research lab dedicated to facilitate research on BSL2-level viruses
- Highly specialized labs to conduct in vitro and in vivo research activities on high-pathogenic BSL3-level viruses
- A fully automated ‘Lab-in-a-box’ screening facility to support high-throughput screening on low- and high-pathogenic viruses
- Dedicated and fully equipped research labs to facilitate discovery of new antiviral strategies
VIRUSBANK PLATFORM FACILITY
Laboratories at Arenberg Accelerator
New 600 m² lab infrastructure equipped to conduct all BSL-2 virus research involving state-of-the-art cell- and organoid-based infection assays as well as specialized in vivo infection models for virus families with high pandemic potential.
VIRUSBANK PLATFORM FACILITY
Laboratories at Bio-Incubator 2
Dedicated and fully-equipped research labs (CD3) to perform discovery of new antiviral therapies, including large compound libraries and world-class medicinal chemistry capabilities.
VIRUSBANK PLATFORM FACILITY
Laboratories at Rega Institute
High-Biosafety laboratories, including a fully automated ‘Lab-in-a-box’ screening facility (Caps-It).
